• D-Luciferin for Cotton Defense Reporter Assays

  2026-09-07

  Translate the GoPGF–JAVL feedback model into quantitative luciferase reporter experiments, while using the same substrate for in vivo bioluminescence imaging and tumor cell tracking. This guide combines assay design, practical dosing ranges, fresh-solution handling, and troubleshooting for reproducible firefly luciferase workflows.

• WRN–MMR Synthetic Lethality in MSI Colon Cancer

  2026-09-05

  This PNAS study explains why mismatch repair-deficient, microsatellite-instable colorectal cancer cells depend on Werner helicase: WRN loss activates a p53–PUMA apoptotic program. Genetic depletion and pharmacologic RecQ helicase inhibition suppressed MSI tumor growth in cell and xenograft models, supporting WRN as a context-dependent therapeutic target in p53-wild-type disease.

• In Vitro Drug Response Metrics and Timing

  2026-09-04

  Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell killing are related but non-equivalent components of an anticancer response. This framework helps researchers design assays that resolve response magnitude, biological composition, and timing rather than treating a single viability endpoint as a complete measure of drug activity.

• ATS-9R: Targeted Gene Silencing in White Fat

  2026-09-04

  ATS-9R enables non-viral delivery of shRNA and sgRNA/Cas9 cargoes to white adipose tissue, including visceral adipose tissue macrophages. This practical guide covers complex formation, tissue-selective validation, metabolic disease applications, and troubleshooting for reproducible gene silencing.

• PD 173074 in FGF-2 Neurotrophic Signaling

  2026-09-03

  The 2000 reference study established PD 173074 as a potent pharmacological tool for separating FGF-2-dependent neuronal survival, neurite outgrowth, and MAPK signaling from effects driven by other neurotrophic factors. Its comparative inhibitor design and cell-based readouts provide a useful framework for studying FGFR1 signaling while highlighting the limits of extrapolating neuronal pharmacology to other biological systems.

• PD 173074: FGFR1 Workflows for Podocyte Research

  2026-09-03

  PD 173074 provides a practical pharmacologic perturbation of FGFR1 signaling for podocyte, diabetic kidney disease, angiogenesis, and cancer research. Its separation between FGFR1 and VEGFR2 activity supports dose-tiered experiments that distinguish pathway mechanism from broader vascular effects.

• Mecamylamine Hydrochloride in Gut-Brain Assays

  2026-09-02

  Use mecamylamine hydrochloride as a reversible pharmacological probe to test whether nicotinic signaling connects intestinal, vagal, and brain readouts. This workflow combines receptor-level validation with microbiota–seizure models while clearly separating mechanistic assay guidance from evidence that remains specific to Bacteroides fragilis.

• PD 173074: FGFR1 Assays from Kidney to Cancer

  2026-09-02

  PD 173074 is a practical ATP-competitive probe for separating FGFR1-dependent signaling from downstream phenotypes in podocyte, cancer, and angiogenesis models. This workflow combines nanomolar pathway engagement with orthogonal controls, helping distinguish target-specific effects from solvent toxicity, receptor cross-talk, and prolonged treatment artifacts.

• Trolox: Mechanism, Assays, and Research Workflows

  2026-09-01

  Trolox, also called 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid, is a vitamin E analogue used to benchmark antioxidant capacity and oxidative injury responses. Its assay value is well established, but biological protection remains dependent on solvent, concentration, cell type, oxidant exposure, and endpoint selection.

• AAL-993: Selective VEGF Receptor Inhibitor

  2026-09-01

  AAL-993 is a selective VEGF receptor inhibitor that preferentially inhibits VEGFR-2 and VEGFR-3 kinase activity over VEGFR-1. Its reported preclinical profile supports use as an anti-angiogenic compound in receptor assays, VEGF-induced angiogenesis models, and melanoma tumor growth inhibition studies, but it does not establish clinical efficacy.

• From Epigenetic Stress to Cell Death in MLL-ALL

  2026-08-31

  A mechanistic and translational framework for using Annexin V-APC/7-AAD to connect epigenetic drug response with apoptosis and necrosis in MLL-rearranged acute lymphoblastic leukemia. The article explains assay biology, experimental controls, competitive advantages, and how to interpret cell-death data without overstating causality.

• AS1842856 Foxo1 Inhibitor: Assay Workflow

  2026-08-31

  Build cleaner Foxo1 experiments with AS1842856 by separating transcription-factor activity from protein abundance. This workflow connects hepatic glucose-production and autophagy research with exploratory PI3K-Akt-Foxo1 studies in mesenchymal stem cells, while distinguishing established evidence from hypothesis-generating applications.

• Intestinal Stretch, Weight Loss, and Satiety Recovery

  2026-08-30

  The reference study shows that intestinal mechanical stretch independently suppresses food intake and improves oral glucose tolerance, while obesity weakens these responses. Both dietary and surgical weight loss restored stretch-related satiety signaling and nucleus of the solitary tract activation, identifying a reversible mechanosensory defect distinct from classical nutrient and GLP-1 pathways.

• Axitinib (AG 013736): From Potency to Translation

  2026-08-29

  A mechanistic and strategic guide to using Axitinib (AG 013736) in VEGF signaling pathway modulation, angiogenesis inhibition assays, and tumor growth inhibition in xenograft models, with emphasis on distinguishing target engagement from nonspecific growth effects.

• Ouabain Workflows for Na+/K+-ATPase Research

  2026-08-28

  Ouabain enables a controlled, extracellular perturbation of sodium-potassium pump activity across cell, vessel, and animal experiments. This practical guide connects Na+/K+-ATPase inhibition to calcium handling, endothelial hyperpolarization, cardiovascular research, and reproducible troubleshooting.

7426 records 2/496 page Previous Next 12345 下5页 Last page